412347-30-9

Basic information

• Product Name: 1-(5-Bromo-3-pyridyl)piperazine
• Synonyms: 1-(5-Bromo-3-pyridyl)piperazine;5-Bromo-3-(piperazin-1-yl)pyridine;1-(5-bromopyridin-3-yl)piperazine;Piperazine,1-(5-bromo-3-pyridinyl)-
• CAS NO: 412347-30-9
• Molecular Formula: C9H12BrN3
• Molecular Weight: 242.12
• Product Categories: pharmacetical
• Mol File: 412347-30-9.mol

Chemical Properties

• Boiling Point: 366.5°Cat760mmHg
• Flash Point: 175.5°C
• Appearance: /
• Density: 1.448g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.58
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-(5-Bromo-3-pyridyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-Bromo-3-pyridyl)piperazine(412347-30-9)
• EPA Substance Registry System: 1-(5-Bromo-3-pyridyl)piperazine(412347-30-9)

Safety Data

• Hazardous Substances Data: 412347-30-9(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry and Drug Discovery:
1-(5-Bromo-3-pyridyl)piperazine is used as a building block for the synthesis of pharmaceuticals and bioactive molecules. Its unique chemical properties make it a valuable component in the development of new drugs and compounds.
Used in Chemical Reactions:
1-(5-Bromo-3-pyridyl)piperazine is used as a reagent in chemical reactions, facilitating the synthesis of various compounds and contributing to the advancement of chemical research.
Used in Research and Development of New Drugs and Compounds:
1-(5-Bromo-3-pyridyl)piperazine has been studied for its potential therapeutic effects in the treatment of various medical conditions. Its unique chemical properties make it a promising candidate for further research and development in the pharmaceutical industry.

InChI:InChI=1/C9H12BrN3/c10-8-5-9(7-12-6-8)13-3-1-11-2-4-13/h5-7,11H,1-4H2

Upstream product

• 110-85-0 piperazine 
• 407-20-5 3-bromo-5-fluoropyridine 
• 625-92-3 3,5-dibromopyridine 

Downstream Products

• 412347-44-5 1-(5,6-dibromopyridin-3-yl)piperazine 
• 1608496-77-0 C₁₉H₂₂N₄O 

Relevant articles and documents

5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS

The present invention discloses compounds according to Formula (I), wherein R, R2, R3a, R3b, and Cy are as defined herein. The present invention discloses compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same and methods for the prophylaxis and/or treatment of inflammatory conditions and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis.

New ligands with affinity for the α4β2 subtype of nicotinic acetylcholine receptors. Synthesis, receptor binding, and 3D-QSAR modeling

A new series of piperazines, diazepanes, diazocanes, diazabicyclononanes, and diazabicyclodecanes with affinity for the α4β 2 subtype of nicotinic acetylcholine receptors were synthesized on the basis of results from a previous computational study. A predictive 3D-QSAR model was developed using the GRID/GOLPE approach (R2 = 0.94, Q 2 = 0.83, SDEP = 0.34). The SAR was interpreted in terms of contour maps of the PLS coefficients and in terms of a homology model of the α4β2 subtype of the nicotinic acetylcholine receptors. The results reveal that hydrogen bonding from both hydrogens on the protonated amine and from the pyridine nitrogen to a water molecule as well as van der Waals interactions between the substituent bearing the protonated amine and the receptor is of importance for ligand affinity. The combination of 3D-QSAR and homology modeling proved successful for the interpretation of structure-affinity relationships as well as the validation of the individual modeling approaches.